Covalent Isothiocyanate Inhibitors of Macrophage Migration Inhibitory Factor as Potential Colorectal Cancer Treatments
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400394 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Lohitha Putha und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. Hauptthemen laut MEDLINE: Isothiocyanates, Macrophage Migration-Inhibitory Factors, Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Otago Research Grant.
Abstract (Originalsprache)
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that has roles in innate and adaptive human immune responses, as well as inflammation. MIF exerts its biological activity by binding to the cell surface receptor CD74 as well as intracellular signalling proteins. MIF also possesses keto‐enol tautomerase activity. Inhibition of the tautomerase activity has been associated with loss of biological activity of MIF and a potential anticancer target. Isothiocyanates (ITCs) are a class of compounds present in cruciferous vegetables that inhibit the MIF tautomerase activity via covalent modification of the N‐terminal proline. A range of substituted ITCs featuring benzyl, phenethyl and phenyl propyl isothiocyanates were designed, synthesised and tested to determine any structure activity relationship for inhibiting MIF. Crystal structures of covalent compounds 8 and 9 in complex with rhMIF revealed key hydrogen bonding and edge‐to‐face π stacking interactions. Compound 9 and 11 with sub micromolar activity were tested in the NCI60 cancer cell lines panel. Both compounds showed tissue‐specific reduced growth in colon and renal cancer cell lines, while one of these showed potent, dose‐dependent inhibition of growth against all seven colon cancer cell lines (GI 50
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
- Department of Biochemistry, School of Biomedical Sciences, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
- Department of Chemistry, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
ORCID-Profile: Matthias Fellner, Malcolm T Rutledge, Allan B Gamble, Sigurd M Wilbanks, Andrea J Vernall, Joel D A Tyndall
Förderung
- University of Otago Research Grant
Zitieren
APA
Putha, L., Kok, L. K., Fellner, M., Rutledge, M. T., Gamble, A. B., Wilbanks, S. M., Vernall, A. J., & Tyndall, J. D. A. (2024). Covalent Isothiocyanate Inhibitors of Macrophage Migration Inhibitory Factor as Potential Colorectal Cancer Treatments. ChemMedChem. https://doi.org/10.1002/cmdc.202400394
Vancouver
Putha L, Kok LK, Fellner M, Rutledge MT, Gamble AB, Wilbanks SM, et al. Covalent Isothiocyanate Inhibitors of Macrophage Migration Inhibitory Factor as Potential Colorectal Cancer Treatments. ChemMedChem. 2024. doi:10.1002/cmdc.202400394
BibTeX
@article{Putha2024,
author = {Putha, Lohitha and Kok, Liang K and Fellner, Matthias and Rutledge, Malcolm T and Gamble, Allan B and Wilbanks, Sigurd M and Vernall, Andrea J and Tyndall, Joel D A},
title = {Covalent Isothiocyanate Inhibitors of Macrophage Migration Inhibitory Factor as Potential Colorectal Cancer Treatments},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400394}
}
EUVIMED